Merck: FDA reviewing its ragweed allergy therapy

Published



WHITEHOUSE STATION, N.J. (AP) — Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.

Merck’s latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue. Patients in studies of the tablet took it daily for a year.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.